Literature DB >> 18565380

Annals of Emergency Medicine Journal Club. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia.

Michael D Menchine1, Tyler W Barrett, David L Schriger.   

Abstract

WHAT IS ALREADY KNOWN ON THIS TOPIC: Procalcitonin is a biomarker that appears to correlate with bacterial infection. WHAT QUESTION THIS STUDY ADDRESSED: Does a procalcitonin level add prognostic information for pneumonia patients in conjunction with scoring systems such as the Pneumonia Severity Index or CURB-65? WHAT THIS STUDY ADDS TO OUR KNOWLEDGE: Among 1,651 patients with community-acquired pneumonia in 28 US emergency departments, procalcitonin levels did not add prognostic information for most pneumonia patients. Among higher-risk groups by Pneumonia Severity Index score, low procalcitonin level predicted lower mortality. HOW THIS MIGHT CHANGE CLINICAL PRACTICE: Clinicians should continue using validated prognostic scoring systems for pneumonia. Low procalcitonin level could be considered as a factor for selected patients who would otherwise be considered high risk to be treated in a lower acuity setting.

Entities:  

Year:  2008        PMID: 18565380     DOI: 10.1016/j.annemergmed.2008.05.033

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  1 in total

1.  Procalcitonin-guided antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease: An updated meta-analysis.

Authors:  Zhuying Li; Xingxing Yuan; Ling Yu; Bingyu Wang; Fengli Gao; Jian Ma
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.